About Us

EpiAxis Therapeutics is pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells (CSC). Specifically, that target is the nuclear bound lysine-specific demethylase 1 (LSD1) & its upstream regulator, the theta isoform of protein kinase C (PKC theta).

The research identifying this target and the intellectual property (IP) that resulted from this was developed by Professor Sudha Rao and colleagues at the University of Canberra (UC), Australia. The Company is focused initially on the prevention of metastatic breast cancer, with other CSC mediated diseases such as ovarian, pancreatic, colon, melanoma, lung and liver cancers to be pursued later.

Read more


Development Overview

Clinical, Pre-clinical & Discovery program

EpiAxis is pursuing three parallel arms to its development plan, namely a clinical, a pre-clinical and a discovery inhibitor arm..

Read more

Management

The people behind EpiAxis

Jeremy Chrisp is a biotechnology entrepreneur with extensive experience in the commercialisation of Australian technology, with a focus on business development and the management of early stage opportunities..

Read more